Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccine for Metastatic Melanoma or Epithelial Cancer
NCT03300843Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2018
- Primary completion
- Jul 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in melanoma, gastrointestinal cancer, breast cancer and 2 more, sponsored by National Cancer Institute. Primary endpoint: Percentage of Patients Who Had a Clinical Response (Complete Response (CR) + Partial Response (PR)) at 6 months. Started Apr 2018; status: terminated.
02
Conditions
melanomagastrointestinal cancerbreast cancerMalignant ovarian neoplasm (OC)carcinoma
Beyond the preview
Go deeper on NCT03300843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03300843.